Chang Liu

Chang Liu

Auto-generated profile, based on publicly available information

Chang Liu

Biomedical Engineering Program, University of South Carolina, Columbia, South Carolina 29208, United States

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2009 in The Journal of Physical Chemistry C
Verified
Journal Article
Closed access
SASubbiah Alwarappan
Subbiah Alwarappan
AEArzum Erdem
Arzum Erdem
CLChang Liu
Chang Liu
CLChen-Zhong Li
Chen-Zhong Li

6 February 2017 in Nature Biomedical Engineering
Verified
Journal Article
Open access
PDF file
KLKai Liang
Kai Liang
FLFei Liu
Fei Liu
JFJia Fan
Jia Fan
DSDali Sun
Dali Sun
CLChang Liu
Chang Liu
THTony Hu
Tony Hu
Tumour-derived extracellular vesicles (EVs) are of increasing interest as a resource of diagnostic biomarkers. However, most EV assays require large samples and are time-consuming, low-throughput and costly, and thus impractical for clinical use. Here, we describe a rapid, ultrasensitive and inexpensive nanoplasmon-enhanced scattering (nPES) assay that directly quantifies tumour-derived EVs from as little as 1 μl of plasma. The assay uses the binding of antibody-conjugated gold nanospheres and nanorods to EVs captured by EV-specific antibodies on a sensor chip to produce a local plasmon effect that enhances tumour-derived EV detection sensitivity and specificity. We identified a pancreatic cancer EV biomarker, ephrin type-A receptor 2 (EphA2), and demonstrate that an nPES assay for EphA2-EVs distinguishes pancreatic cancer patients from pancreatitis patients and healthy subjects. EphA2-EVs were also informative in staging tumour progression and in detecting early responses to neoadjuvant therapy, with better performance than a conventional enzyme-linked immunosorbent assay. The nPES assay can be easily refined for clinical use, and readily adapted for diagnosis and monitoring of other conditions with disease-specific EV biomarkers.

1 March 2010 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
CLChang Liu
Chang Liu
SASubbiah Alwarappan
Subbiah Alwarappan
ZCZhongfang Chen
Zhongfang Chen
XKXiangxing Kong
Xiangxing Kong
CLChen-Zhong Li
Chen-Zhong Li

12 July 2010 in The Journal of Physical Chemistry C
Verified
Journal Article
Closed access
SASubbiah Alwarappan
Subbiah Alwarappan
CLChang Liu
Chang Liu
AKAshok Kumar
Ashok Kumar
CLChen-Zhong Li
Chen-Zhong Li

27 March 2017 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
CLChang Liu
Chang Liu
ZZZhen Zhao
Zhen Zhao
JFJia Fan
Jia Fan
CLChristopher J. Lyon
Christopher J. Lyon
HWHung-Jen Wu
Hung-Jen Wu
THTony Hu
Tony Hu
Significance: Active Mycobacterium tuberculosis ( Mtb ) infections represent a significant global health threat, but can be difficult to diagnose and manage owing to the nonquantitative nature and relatively poor performance of current frontline sputum-based diagnostic assays, which can be further degraded by certain Mtb manifestations. This study describes the development of a rapid and quantitative blood-based assay with high sensitivity and specificity for active Mtb infections that can be used to monitor responses to antimycobacterial therapy. Our method combines antibody-labeled, energy-focusing nanodisks with high-throughput mass spectrometry to enhance the detection of Mtb -specific peptides in digested serum samples, and should allow rapid clinical translation. This approach also should be applicable to other infectious diseases, particularly those for which conventional immunoassays exhibit suboptimal performance.

25 July 2023 in ACS Nano
Verified
Journal Article
Closed access
XWXiaojun Wei
Xiaojun Wei
TPTadas Penkauskas
Tadas Penkauskas
JRJoseph E. Reiner
Joseph E. Reiner
CKCeleste Kennard
Celeste Kennard
Mark UlineMark Uline
Mark Uline
CLChang Liu
Chang Liu